<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106441</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0046</org_study_id>
    <nct_id>NCT03106441</nct_id>
  </id_info>
  <brief_title>Preoxygenation Optimisation in Obese Patients</brief_title>
  <acronym>PREOPTI-POOP</acronym>
  <official_title>PREOPTI-POOP: Preoxygenation Optimisation in Obese Patients: High-flow Nasal Cannula Oxygen Versus Non-invasive Ventilation : A Single-centre Randomized Controlled Study. &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oro-tracheal intubation in operating room in obese patients with BMI &gt; 35kg/m2 remains a
      critical event. The aim of this study is to determine whether Nasal High Flow Therapy by
      nasal cannula Optiflow® is more efficient than the BIPAP preoxygenation before orotracheal
      intubation after crash induction in obese patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be designed as followed : Patients will be randomized in 2 groups :

        -  Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 (fraction of
           inspired oxygen) = 1) before orotracheal intubation after crash induction. The device
           will be maintained in place throughout the intubation procedure in order to achieve
           apnoeic oxygenation.

        -  Or Preoxygenation during 4 minutes with Bi-level Positive Airway Pressure (BIPAP) with
           Expiratory Positive Airway Pressure (EPAP) + 10 cm H2O and Inspiratory Airway Positive
           Airway Pressure (IPAP) + 25, meaning a 15cm H2O pressure support. The facial mask with
           be removed after before crash induction enabling laryngoscopic vision.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">June 21, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expired fraction of oxygen at the end of intubation</measure>
    <time_frame>2 minutes</time_frame>
    <description>To determine whether High-Flow nasal cannula used during the preoxygenation in obese patient is more efficient than BIPAP preoxygenation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of preoxygenation</measure>
    <time_frame>4 minutes</time_frame>
    <description>duration of proceedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in side effects incidence related to intubation</measure>
    <time_frame>1 hour</time_frame>
    <description>Notification of adverse events during the intubation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbi-mortality during surgery</measure>
    <time_frame>6 hour</time_frame>
    <description>Per and postoperative complication rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Severe Obesity Design as BMI &gt; 35kg/m2</condition>
  <arm_group>
    <arm_group_label>High flow oxygen therapy by nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Device : High flow oxygen therapy by nasal cannula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facial mask oxygenation in BIPAP ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: Facial mask oxygenation in BIPAP ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow oxygen therapy by nasal cannula. Optiflow®</intervention_name>
    <description>Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.</description>
    <arm_group_label>High flow oxygen therapy by nasal cannula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Facial mask oxygenation in BIPAP ventilation</intervention_name>
    <description>Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision</description>
    <arm_group_label>Facial mask oxygenation in BIPAP ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese patient with BMI &gt; 35kg/m2

          -  Age between 18 and 80 years

          -  Requiring a crash induction sequence for oro-tracheal intubation.

        Exclusion Criteria:

          -  Pulse oxymetry &lt; 90% in ambient air

          -  Haemodynamic instability

          -  Burned patient

          -  Indication of intubation vigil in spontaneous ventilation

          -  Patients with a documented Cormack IV exposition before inclusion

          -  Protected adult

          -  Pregnancy

          -  Lack of consent

          -  Patient already enrolled in an other randomized study looking forward improving
             preoxygenation quality.

          -  Lack of French social protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Asehnoune, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Asehnoune, PHD</last_name>
    <phone>02.44.76.68.90</phone>
    <email>Karim.ASEHNOUNE@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mickael Vourc'h, MD</last_name>
    <phone>02.44.76.80.53</phone>
    <email>Mickael.VOURCH@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes University Hospital, Hôtel Dieu, Medical intensive care unit</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Asehnoune, PHD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mickael Vourc'h, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karim Asehnoune, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mickael Vourc'h, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

